Abstract P5-16-02: Updated efficacy, safety and translational data from MARIO-3, a phase II open-label study evaluating a novel triplet combination of eganelisib (IPI-549), atezolizumab (atezo), and nab-paclitaxel (nab-pac) as first-line (1L) therapy for locally advanced or metastatic triple-negative breast cancer (TNBC)
Hatem, Soliman, Hargis, Jeffrey, Elias, Anthony, Lee, Arielle, Swart, Rachel, Dahkil, Shaker, Drakaki, Alexandra, Phan, Vu, Kass, Frederic, Cobleigh, Melody, Babu, Sanil, Tkaczuk, Katherine, O'Connell, Brenda, Roberts, Jennifer, Zizlsperger, Nora, Hamilton, Erika
Published in Cancer research (Chicago, Ill.) (15.02.2022)
Published in Cancer research (Chicago, Ill.) (15.02.2022)
Get full text
Journal Article